Back to Search
Start Over
Interferon Alpha-2a for the Treatment of Cystoid Macular Edema Secondary to Acute Retinal Necrosis.
- Source :
-
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2022 Oct-Nov; Vol. 30 (7-8), pp. 1788-1797. Date of Electronic Publication: 2021 Aug 04. - Publication Year :
- 2022
-
Abstract
- Purpose: To report the results of interferon (IFN) α-2a treatment in patients with cystoid macular edema (CME) secondary to acute retinal necrosis (ARN).<br />Methods: We reviewed the records of seven patients (eight eyes) who received IFNα-2a for post-ARN CME. The initial dose of IFNα-2a was 3 MIU/day and it could be tapered down to 3 MIU twice a week. Efficacy was assessed by central macular thickness (CMT) on spectral-domain optical coherence tomography and visual acuity.<br />Results: Age range of seven patients (four men, three women) was 36-74 years. Mean CMT decreased from 477.9 ± 167.5 μm to 367.3 ± 120.5 μm at first week, and vision improved up to five lines in five eyes. CME relapsed after cessation of IFNα-2a in all and improved following reinstitution of treatment. Treatment was discontinued in one patient because of depression. Three patients electively discontinued treatment due to poor tolerability or lack of functional improvement.<br />Conclusion: IFNα-2a is an effective therapeutic option for post-ARN CME, though side effects such as fatigue, elevated liver enzymes, neutropenia, and depression may limit tolerability. Lower initial doses may be a better tolerated.
Details
- Language :
- English
- ISSN :
- 1744-5078
- Volume :
- 30
- Issue :
- 7-8
- Database :
- MEDLINE
- Journal :
- Ocular immunology and inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 34348058
- Full Text :
- https://doi.org/10.1080/09273948.2021.1957121